Catalent Increases Sterile Fill-Finish Manufacturing Capacity At Its Research Triangle Park Facility In North Carolina

Catalent Increases Sterile Fill-Finish Manufacturing Capacity At Its Research Triangle Park Facility In North Carolina

Somerset, NJ, June 5, 2012 — Catalent Pharma Solutions announced today the completion of the construction of its newly renovated 3,300 square foot aseptic fill-finish manufacturing facility at Research Triangle Park (RTP), NC.

Catalent has a comprehensive sterile product formulation and development offering at its RTP site.  The product development group conducts preformulation, formulation development, process development and manufacturing support in addition to offering full service analytical development and stability capabilities.

The state-of-the-art sterile clinical manufacturing suite will provide Class A manufacturing space containing a flexible aseptic vial filling line capable of producing Phase I and Phase II clinical trial materials. These fill finish facilities are designed to comply with global GMP requirements.

This renovation provides four-fold increase of the sterile fill-finish capacity at the Catalent RTP site and adds a new complementary technology to Catalent's existing service offerings.  "It is part of Catalent's ongoing investment to provide integrated solutions to meet biologic and biosimilar drug development companies' growing needs," commented Christine Dolan, Vice President and General Manager of Catalent's Development and Analytical Solutions business. "Combined with Catalent's GPEx® technology, expert biopharmaceutical lab services capabilities, world leading clinical trial supply services and commercial manufacturing capabilities, we will be able to help our customers bring more products from gene to market."

For more information on Catalent's drug development services, please click the link: www.catalent.com/development-services

For more information on Catalent's clinical supply services and commercial manufacturing capabilities, please click the link:  www.catalent.com/css

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

WCG is continuing its buyout run after acquiring clinical trial solutions firm Trifecta Clinical.

London-based uMed has raised nearly $4.8 million from U.K. and U.S. VCs to help healthcare providers participate in more clinical studies.

Amgen has teamed up with cloud-based trial solutions firm Reify Health to help boost patients into its drug studies.